Semaglutide (Wegovy) for Alcohol Use Disorder: Cautious Optimism and Current Research Limitations

The podcast discusses the emerging news regarding semaglutide (Wegovy), a GLP-1 receptor agonist, as a potential treatment for alcohol use disorder (AUD). While acknowledging the cautious optimism surrounding this development, the host emphasizes that it is not a "magic bullet." The core mechanism involves semaglutide's interaction with the leptin-GLP-1-dopamine system, aiming to reduce hunger and increase the metabolism of dopamine in the presence of alcohol, thereby potentially diminishing alcohol's rewarding effects and motivation for consumption.

The discussion highlights two primary studies: a Danish study using exenatide (a similar GLP-1 agonist) with 127 participants, and an American case series using semaglutide with only six patients. A critical nuance from the Danish study is that exenatide was administered *in addition to standard cognitive behavioral therapy (CBT)*, suggesting that the medication alone may not be sufficient. Furthermore, while the exenatide group showed reduced fMRI alcohol cue reactivity and lower AUDIT scores (indicating fewer cravings), there was no significant difference in *total alcohol intake* or *heavy drinking days* between the treatment and placebo groups when both received CBT. The American study, being a small case series, offers anecdotal evidence but lacks statistical generalizability.

The host stresses the significant limitations of current research, particularly regarding generalizability. The Danish study's participants were all white, mean age 52, and predominantly male, making it difficult to apply findings to diverse populations. The American study's minuscule sample size (six patients) further restricts broad conclusions. Practical considerations include the high cost of semaglutide (around $1500/month) and the potential need for lifelong treatment, as patients often relapse or regain weight upon discontinuation. The podcast also raises a speculative concern that if alcohol no longer provides a dopamine boost, individuals might seek other substances to self-medicate.

The broader implications suggest that semaglutide might be effective for a specific subset of AUD patients, potentially those who are also obese, hinting at a shared underlying mechanism between binge eating, obesity, and alcoholism. However, the current evidence is too preliminary to warrant widespread excitement or to position semaglutide as a standalone solution. The podcast implicitly advocates for a holistic approach to addiction treatment, integrating pharmacological interventions with behavioral therapies like CBT, and emphasizes the importance of weighing costs, benefits, and potential side effects with a doctor, especially when considering alternatives like Vivitrol.

"I wanted to go over that a little bit and encourage people to not assume it's the next Magic Bullet so to speak."

"semaglutide is a glp1 receptor Agonist which acts to reduce that hunger and increase the metabolism of dopamine in the presence of alcohol."

"a lot of people with addictions actually engage in their addictive behaviors because they have done so much damage to their dopamine system that they're trying to artificially do whatever they can to self-medicate and get their dopamine levels up to where it should be."

"you have to have the CBT all patients were white with a mean age of 52 years and the majority of the patients were men."

"we can't generalize the results from this to people of different ethnicities we can't generalize it to young people or people who are significantly older and we need to be careful about how much generalization we do between biological genders."

"the exenatide did however attenuate the functional magnetic resonance imaging alcohol Q reactivity in the ventral striatum and sepal area."

"it's possible that this particular treatment may be effective for people who are obese at the same time there may be a mechanism that is contributing to Bing eating and obesity and alcoholism that may be addressed by this uh medication."

"this is a case study because there were only six people in it and it's really hard to draw any generalizable conclusions from six people."